Harvard Bioscience, Inc.

NasdaqGM:HBIO Stock Report

Market Cap: US$104.2m

Harvard Bioscience Management

Management criteria checks 2/4

Harvard Bioscience's CEO is Jim Green, appointed in Jul 2019, has a tenure of 5.33 years. total yearly compensation is $2.39M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 4.38% of the company’s shares, worth $4.56M. The average tenure of the management team and the board of directors is 2 years and 7.1 years respectively.

Key information

Jim Green

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage24.5%
CEO tenure5.3yrs
CEO ownership4.4%
Management average tenure2yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Nov 07
Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

CEO Compensation Analysis

How has Jim Green's remuneration changed compared to Harvard Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$2mUS$586k

-US$3m

Sep 30 2023n/an/a

-US$3m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$574k

-US$10m

Sep 30 2022n/an/a

-US$7m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$3mUS$574k

-US$288k

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$3m

Mar 31 2021n/an/a

-US$4m

Dec 31 2020US$3mUS$574k

-US$8m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$3mUS$265k

-US$5m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019n/an/a

US$432k

Mar 31 2019n/an/a

-US$819k

Dec 31 2018US$153kn/a

-US$4m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$7m

Dec 31 2017US$129kn/a

-US$2m

Compensation vs Market: Jim's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD651.15K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


CEO

Jim Green (66 yo)

5.3yrs

Tenure

US$2,392,240

Compensation

Mr. James W. Green, also known as Jim, has been the Chairman of Harvard Bioscience, Inc. since June 5, 2017 and its Director since April 30, 2015. He serves as President and Chief Executive Officer of Harv...


Leadership Team

NamePositionTenureCompensationOwnership
James Green
President5.3yrsUS$2.39m4.38%
$ 4.6m
Jennifer Cote
CFO & Treasurer1.8yrsUS$571.27k0.097%
$ 100.7k
John Fry
Chief Legal Counsel & Corporation Secretary2.3yrsno datano data
Ryan Wallace
Senior Vice President of Global Sales1.5yrsno datano data
Lori Packer
Vice President of Global People Operationsno datano datano data
Kathryn Flynn
Corporate Controllerno datano datano data
David Sirois
Director of Corporate Accounting & SEC Reportingno datano datano data

2.0yrs

Average Tenure

63yo

Average Age

Experienced Management: HBIO's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Green
President9.6yrsUS$2.39m4.38%
$ 4.6m
Alan Edrick
Independent Director5.2yrsUS$213.09k0.52%
$ 545.0k
Bertrand Loy
Lead Independent Director10yrsUS$223.06k1.15%
$ 1.2m
Thomas Loewald
Independent Director7.1yrsUS$205.45k0.57%
$ 596.2k
Katherine Eade
Independent Director7.1yrsUS$198.09k0.61%
$ 634.0k

7.1yrs

Average Tenure

58yo

Average Age

Experienced Board: HBIO's board of directors are considered experienced (7.1 years average tenure).